In a recent transaction, Svend Andersen, EVP & President of Consumer Health Care International (CHCI) at Perrigo Co plc (NYSE:PRGO), invested $27,900 in the company's stock. The transaction, which took place on May 28, 2024, involved the purchase of 1,000 ordinary shares at a price of $27.9 each.
This purchase by a high-ranking executive is a notable event for investors, as it reflects a direct investment in the company's future by one of its leaders. Following this transaction, Andersen's total direct holdings in Perrigo Co have increased to 101,853 shares.
Perrigo Co, headquartered in Dublin, Ireland, is a leading provider of over-the-counter health and wellness solutions. The company's commitment to providing affordable self-care products positions it well in the pharmaceutical preparations industry.
Investors often look to the buying and selling activities of company executives as an indicator of the company's financial health and the executives' confidence in the company's future performance. Andersen's purchase aligns with such perspectives, potentially signaling his positive outlook on Perrigo's prospects.
The details of this transaction were made public through a Form 4 filing with the Securities and Exchange Commission, as required by federal securities laws. The filing provides transparency into the trading activities of company insiders, offering investors insight into the actions of Perrigo's executive team.
Perrigo Co's stock, traded under the ticker PRGO, is watched by investors who follow the health care sector closely. The company's performance, along with the investment decisions of its executives, are key factors that can influence the stock's movement in the market.
As of the signature date on May 31, 2024, the transaction has been duly signed by Victor Torres, attorney-in-fact for Mr. Svend Andersen, affirming the accuracy and completion of the reported information.
InvestingPro Insights
In the wake of the recent insider purchase by Svend Andersen, EVP & President of Consumer Health Care International at Perrigo Co plc, investors may be curious about the broader financial picture of the company. According to InvestingPro data, Perrigo has a market capitalization of approximately $3.75 billion. The company's performance over the last twelve months as of Q1 2024 shows a gross profit of $1.624 billion with a gross profit margin of 35.65%, which may indicate efficient control over production costs and a strong position in the over-the-counter health and wellness market.
Despite a challenging revenue growth rate of -0.06% over the last twelve months as of Q1 2024, Perrigo's dividend yield stands at an attractive 4.04%. This could be particularly appealing to income-focused investors, especially considering that Perrigo has maintained dividend payments for 22 consecutive years, as highlighted by an InvestingPro Tip. Additionally, the company's stock is trading near its 52-week low, which might present a value opportunity for long-term investors.
An InvestingPro Tip also suggests that Perrigo's net income is expected to grow this year, which could be a sign of recovering financial health and potential for future stock price appreciation. For investors interested in further analysis and tips, there are additional insights available on InvestingPro, which currently lists 9 more tips for Perrigo. These insights can be accessed at: https://www.investing.com/pro/PRGO. Moreover, users can take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.